HRW Synapse, our in-house specialist neuroscience team, attended the EAN Congress 2025, uncovering fresh perspectives on Myasthenia Gravis (MG). Alongside behavioural themes identified by HRW Shift, our behavioural science experts, we’ve distilled three critical insights shaping the future of MG care. 1 – Bridging the Gap: Meaningful Endpoints in Myasthenia Gravis Patients living with Myasthenia Gravis often feel that clinical assessments, such as QMG scores, don’t fully capture their day-to-day challenges. Despite being labelled “stable,” many continue to experience: • Persistent fatigue • Fluctuating symptoms • Limitations in daily activities This disconnect reveals a need to redefine treatment success. For patients, meaningful endpoints include the ability to work, socialise, and maintain independence—outcomes that go beyond traditional clinical metrics. 2 – Moving Away from Corticosteroids The rise of C5 inhibitors is reshaping early treatment strategies for Myasthenia Gravis. Clinicians are increasingly adopting a steroid-sparing approach, driven by: • Recognition of long-term steroid side effects (e.g., cardiovascular and metabolic risks) • Updated clinical guidelines • Real-world evidence supporting reduced corticosteroid reliance This shift prioritises patient safety while maintaining effective disease control. 3 – A New Treatment Paradigm for Myasthenia Gravis Targeted therapies, particularly C5 inhibitors like Ravulizumab and Zilucoplan, are transforming the MG treatment landscape. These agents offer: • Rapid symptom relief • Sustained efficacy • Convenient administration, including self-injection Healthcare providers are now considering these therapies earlier in the treatment pathway, moving away from traditional rescue options such as plasma exchange or IVIg. Behavioural Insight: The Halo Effect in MG Treatment Perception The Halo Effect describes how positive perceptions in one area influence broader impressions. In the context of Myasthenia Gravis, the success of C5 inhibitors has created a favourable bias toward similar therapies. While this momentum benefits new entrants, differentiation remains critical. Applying the 80/20 principle may help: • 80% alignment with established expectations • 20% distinct value to stand out in a crowded space Explore the evolving MG landscape and connect with our team at HRW_Synapse@hrwhealthcare.com, alternatively, please fill out the contact form below. Apply Now!